#Obinutuzumab is a humanized monoclonal antibody used as a combination treatment with chlorambucil to treat patients with untreated chronic lymphocytic leukemia. It was approved by the FDA in November 2013 and is marketed under the brand name Gazyva. There is a black box warning of fatal Hepatitis B Virus (HBV) reactivation and fatal Progressive Multifocal #Leukoencephalopathy (PML).
Obinutuzumab is an antineoplastic CD20 antibody used to treat untreated chronic lymphocytic leukemia in combination with chlorambucil.
Obinutuzumab is used as a combination treatment with chlorambucil to treat patients with untreated chronic lymphocytic leukemia.
#cancersucks #cancersurvivor #cancerseason #breastcancersurvivor #americancancersociety #cancersupport #cancers #cancersurvivors #breastcancersucks #kickcancersbutt #macmillancancersupport #breastcancersupport #cancersign #breastcancersurvivors #cancersux #kickingcancersbutt #kickingcancersass #ovariancancersurvivor #childhoodcancersucks #thyroidcancersurvivor #canadiancancersociety #cancersociety #cancerslayer #cancerslug #nationalcancersurvivorsday #irishcancersociety #cancersrock #cancerstinks #cancerszn #childhoodcancersurvivor #cancersticks #cancersun #cancersbelike #teamcancers #braincancer #coloncancersurvivor #caninecancer #pancreaticcancer #skincancer
Drug Today Medical Times (DTMT) is a leading medical and health news portal engaged in bridging the gap between the helathcare professionals and pharma industry for common man across India.
This bilingual channel is dedicated to bring news and views on health and medicine, catering to the health concious people in a form that is easily comprehensable for common man and health professionals at the same time
It not only serves the interest of the healthcare sector but also plays as a bulwark of medical industry safeguarding its core interests and guiding it in its service delivery.
We at Drug Today Medical Times are concious responsibities towards the society and tries to present news in an objective way without sensationalising the issue.
Please subscribe and share our channel for authentic, objective, health realed news
@DrugTodayMedicalTimes
We are also on #facebbok & #instagram
To follow us:
Instagram: [ Ссылка ]
Facebook: [ Ссылка ]
Twitter: [ Ссылка ]
